Otros idiomas Kancera AB

Acciones

KAN

SE0015658570

Diferido Nasdaq Stockholm Otros sitios de cotización 09:41:06 07/05/2024			Varia. Cinco días.	Varia. 1 de enero.
1,456 ^SEK	+0,41 %		-0,95 %	-67,96 %

03/05	Kancera AB (publ) informa de resultados positivos del estudio clínico de fase I con KAND145 en sujetos sanos	CI
23/02	Kancera AB (publ) presenta los resultados del ejercicio cerrado el 31 de diciembre de 2023	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

Kancera meets the primary objectives of the KAND145 clinical phase I study	03/05
Kancera AB Reports Positive Results from the Clinical Phase I Study with KAND145 in Healthy Subjects	03/05
Kancera announces the outcome of the company's rights issue	20/03
Kancera publishes prospectus in connection with the company’s rights issue	01/03
Kancera resolves on a rights issue of approximately SEK 121.9 million	23/02
Interim Report Fourth Quarter 2023, October 1 – December 31 Kancera AB (publ.), org.no. 556806-8851	23/02
Kancera signs license agreement and obtains global commercial rights to the results from the FRACTAL study	23/02
Kancera AB Reports Earnings Results for the Full Year Ended December 31, 2023	23/02
Kancera AB Signs A License Agreement with the University of Newcastle	23/02
Kancera AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	23/02
Kancera presents the statistical analysis of top line data from the FRACTAL study	06/02
Kancera AB Presents the statistical Analysis of Top Line Data from the FRACTAL Study	06/02
Kancera reports positive top line results from the FRACTAL study	20/12
Kancera AB Reports Positive Top Line Results from the FRACTAL Study	20/12
Kancera provides operational update in connection with release of financial interim report for third quarter 2023	17/11
Interim Report Third Quarter July 1 – September 30, 2023 Kancera AB (publ.), org.no. 556806-8851	17/11
Kancera AB Provides Operational Update Regarding Fractalkine Block Blockers KAN567 and KAND145	17/11
Kancera AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	17/11
Kancera reports that the phase I study of KAND145 has received regulatory approval	23/10/23
Kancera AB Receives Finnish Regulatory Agency Approval for Phase I Study of KAND145	23/10/23

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Kancera AB

Acciones

KAN

SE0015658570

Otros idiomas

Filtros